Hugel, Inc.

KOSDAQ:A145020 Stock Report

Market Cap: ₩2.9t

Hugel Valuation

Is A145020 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A145020 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A145020 (₩268500) is trading below our estimate of fair value (₩545309.6)

Significantly Below Fair Value: A145020 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A145020?

Key metric: As A145020 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A145020. This is calculated by dividing A145020's market cap by their current earnings.
What is A145020's PE Ratio?
PE Ratio26.5x
Earnings₩111.17b
Market Cap₩2.95t

Price to Earnings Ratio vs Peers

How does A145020's PE Ratio compare to its peers?

The above table shows the PE ratio for A145020 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average85x
A302440 SK bioscienceLtd
128.1x25.1%₩3.5t
A214450 PharmaResearch
23.8x24.6%₩2.2t
A086900 Medy-Tox
180.6x68.1%₩830.0b
A290650 L&C BIOLTD
7.4xn/a₩363.0b
A145020 Hugel
26.5x20.7%₩2.9t

Price-To-Earnings vs Peers: A145020 is good value based on its Price-To-Earnings Ratio (26.5x) compared to the peer average (85x).

Price to Earnings Ratio vs Industry

How does A145020's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A145020 26.5xIndustry Avg. 30.0xNo. of Companies11PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A145020 is good value based on its Price-To-Earnings Ratio (26.5x) compared to the Asian Biotechs industry average (30x).

Price to Earnings Ratio vs Fair Ratio

What is A145020's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A145020 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.5x
Fair PE Ratio24.1x

Price-To-Earnings vs Fair Ratio: A145020 is expensive based on its Price-To-Earnings Ratio (26.5x) compared to the estimated Fair Price-To-Earnings Ratio (24.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A145020 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩268,500.00
₩360,666.67
+34.3%
14.1%₩470,000.00₩290,000.00n/a12
Nov ’25₩267,500.00
₩328,636.36
+22.9%
9.5%₩360,000.00₩260,000.00n/a11
Oct ’25₩239,500.00
₩313,500.00
+30.9%
15.5%₩400,000.00₩235,000.00n/a10
Sep ’25₩272,500.00
₩313,500.00
+15.0%
15.5%₩400,000.00₩235,000.00n/a10
Aug ’25₩246,500.00
₩260,555.56
+5.7%
26.1%₩400,000.00₩180,000.00n/a9
Jul ’25₩234,000.00
₩260,555.56
+11.3%
26.1%₩400,000.00₩180,000.00n/a9
Jun ’25₩191,000.00
₩224,888.89
+17.7%
12.3%₩270,000.00₩180,000.00n/a9
May ’25₩211,500.00
₩218,777.78
+3.4%
10.1%₩250,000.00₩180,000.00n/a9
Apr ’25₩198,200.00
₩211,444.44
+6.7%
10.3%₩250,000.00₩180,000.00n/a9
Mar ’25₩183,900.00
₩201,750.00
+9.7%
8.3%₩235,000.00₩180,000.00n/a8
Feb ’25₩160,000.00
₩185,625.00
+16.0%
6.2%₩210,000.00₩170,000.00n/a8
Jan ’25₩149,400.00
₩179,875.00
+20.4%
7.8%₩210,000.00₩160,000.00n/a8
Dec ’24₩153,000.00
₩173,625.00
+13.5%
13.3%₩210,000.00₩125,000.00n/a8
Nov ’24₩138,100.00
₩161,142.86
+16.7%
11.7%₩190,000.00₩125,000.00₩267,500.007
Oct ’24₩125,000.00
₩155,428.57
+24.3%
12.7%₩190,000.00₩125,000.00₩239,500.007
Sep ’24₩111,800.00
₩159,250.00
+42.4%
13.3%₩190,000.00₩125,000.00₩272,500.008
Aug ’24₩104,700.00
₩174,500.00
+66.7%
17.2%₩223,000.00₩125,000.00₩246,500.008
Jul ’24₩110,000.00
₩174,500.00
+58.6%
17.2%₩223,000.00₩125,000.00₩234,000.008
Jun ’24₩111,700.00
₩175,750.00
+57.3%
16.9%₩223,000.00₩125,000.00₩191,000.008
May ’24₩113,400.00
₩181,571.43
+60.1%
17.0%₩223,000.00₩130,000.00₩211,500.007
Apr ’24₩127,900.00
₩189,714.29
+48.3%
12.2%₩223,000.00₩150,000.00₩198,200.007
Mar ’24₩129,100.00
₩186,000.00
+44.1%
12.8%₩223,000.00₩150,000.00₩183,900.008
Feb ’24₩145,800.00
₩178,625.00
+22.5%
12.0%₩223,000.00₩150,000.00₩160,000.008
Jan ’24₩134,900.00
₩174,500.00
+29.4%
13.0%₩223,000.00₩150,000.00₩149,400.008
Dec ’23₩116,400.00
₩171,000.00
+46.9%
9.5%₩195,000.00₩150,000.00₩153,000.008
Nov ’23₩113,100.00
₩168,875.00
+49.3%
11.8%₩195,000.00₩130,000.00₩138,100.008

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Medy-Tox

₩830.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩123,300.00

7D

-10.8%

1Y

-41.6%

J2KBIO

₩54.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,490.00

7D

-13.3%

1Y

n/a

Dong-A ST

₩588.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩65,500.00

7D

-12.1%

1Y

15.4%